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Abstract
The advent of nanomedicine marks an unparalleled opportunity to advance the treatment of a 
variety of diseases, including cancer. The unique properties of nanoparticles, such as large surface-
to volume ratio, small size, the ability to encapsulate a variety of drugs, and tunable surface 
chemistry, gives them many advantages over their bulk counterparts. This includes multivalent 
surface modification with targeting ligands, efficient navigation of the complex in vivo 
environment, increased intracellular trafficking, and sustained release of drug payload. These 
advantages make nanoparticles a mode of treatment potentially superior to conventional cancer 
therapies. This article highlights the most recent developments in cancer treatment using 
nanoparticles as drug-delivery vehicles, including promising opportunities in targeted and 
combination therapy.
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Nanomedicine in cancer therapy
Nanomedicine (see Glossary) is the design and development of therapeutics and diagnostic 
tools, distinguished by the nanoscopic scale of its delivery vehicles and diagnostic agents 
[1]. The nanomedical field is rapidly gaining recognition through developing ways of 
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administering treatment, particularly anticancer therapy, with unprecedented safety and 
efficiency. Researchers have improved upon the current standards in drug delivery relating 
to biodistribution, intracellular uptake, and dosing efficacy by utilizing nanoparticles (NPs) 
to encapsulate therapeutics and target sites of disease [2]. The successful application of 
processes to improve the delivery of biomedical entities through functional NPs is a 
revolutionary approach to disease treatment. Several liposome and polymer-based 
therapeutic NPs have been approved by the Food and Drug Administration (FDA) for 
clinical use [1]. This review will discuss the NPs under investigation with an emphasis on 
systems that have reached clinical trials (Table 1).
NPs are minute particles, typically less than 200 nm in diameter. Their nanoscopic size 
facilitates intracellular uptake. NPs have the ability to encapsulate therapeutics and release 
them in a controlled manner to specifically target diseased cells. NP encapsulation also 
improves the solubility of unmodified drug compounds [3]. Additional advantages of NPs 
have brought widespread attention to the field of nanomedicine, including their large ratio of 
volume-to surface area, modifiable external shell, biodegradability, and low cytotoxicity [4]. 
Furthermore, nanomedicine brings us dramatically closer to realizing the full promise of 
personalized medicine [5].
Engineered therapeutic NPs offer numerous clinical advantages. Surface modification with 
polyethylene glycol (PEG) protects NPs from clearance from the blood by the mononuclear 
phagocytic system (MPS), markedly increasing both circulation times and drug uptake by 
target cells [2,6]. Functionalization of the NP surface with multivalent targeting moieties not 
only improves drug efficacy but simultaneously reduces dosage, providing a novel method 
to optimize drug pharmacokinetics [6]. NPs spatially localize through passive/active 
targeting and are capable of delivering drugs through epi/endothelial barriers [3]. Below we 
present some examples of engineered NPs and their features that have been designed to 
address existing challenges in drug delivery, with a specific focus on cancer therapy.
Nanoparticles increase drug solubility, mitigate cytotoxicity, and improve drug 
pharmacokinetic profiles, as exemplified by nanomedicines such as Doxil® and Genexol-
PM®. The last decade has witnessed a number of new biotechnological approaches to the 
treatment of cancer. For example, the 2006 Nobel Prize in Physiology or Medicine brought 
renewed focus on gene silencing, and the therapeutic opportunities offered by precise 
regulation of gene expression have fostered the interest of medical stakeholders in siRNA 
and miRNA technologies [7]. Nevertheless, delivering nucleic acids into cells is challenging 
to say the least: nucleic acids are vulnerable to nucleases ubiquitous in the blood, and their 
dense negative charges hinder cell internalization. Furthermore, the non-specific interferon 
response triggered by the presence of foreign nucleic acids in the cytoplasm is also a major 
impediment to clinical translation [7–9]. To avoid these drawbacks, the ideal siRNA 
delivery system should efficiently encapsulate the negatively charged siRNA molecule, 
prevent degradation by endogenous enzymes, and facilitate cellular uptake and intracellular 
release.
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Technologies already in clinical trials addressing the delivery of RNAi therapeutics will be 
presented in the following sections. The last section will highlight some examples of current 
trends and novel applications of nanomedicine in the field of combination therapy.
Methods of nanoparticle preparation
Their nano-scale size means that NPs require a very specialized formulation method. The 
most common methods employ self-assembly processes to amphiphilic lipid, polymer, or 
polymerdrug conjugates. Such processes include nanoprecipitation, oil-in-water (O/W) 
single emulsion, and water-in-oil-in-water (W/O/W) double emulsification [10–12]. The 
most recent development in the synthesis of NPs involves the discipline of microfluidics, 
which is capable of manipulating nano-scale volumes in micro-scale fluidic channels [13]. 
Microfluidic reactors offer precise control and manipulation of the fluids used to create NPs. 
Micro-scale channels offer the advantage of a very large surface-to-volume ratio and 
controllable mixing time, which promotes higher NP yield and uniform size [14,15]. 
Through multi-inlet mixing at different ratios and hydrodynamic flow focusing, the NPs 
self-assemble through diffusive mass transfer at the interface of miscible liquids (Figure 1) 
[12]. Other significant advantages of microfluidics include the reproduciblility of device 
fabrication and rapid, consistent NP synthesis with narrow size distributions [14]. 
Microfluidic devices are tunable and can use 3D hydrodynamic focusing to create NPs of 
different sizes and targeting ligand densities with multiple polymers, which can in turn 
produce diverse NP libraries (Figure 1) [16,17]. In addition, microfluidics provides a means 
to rapidly and continuously form consistent nano- and micro-structures while 
simultaneously encapsulating drugs, which is not readily feasible with conventional 
approaches [18,19]. However, to take full advantage of the benefits of microfluidic 
nanoformulation, the challenges associated with the high costs of glass/silicon fabrication 
and large-scale production for clinical use still need to be addressed [14].
“Stealth” modification of NPs
Modification with PEG is currently the gold standard for NP coating [10,20,21]. PEG 
surface functionalization has been shown to dramatically reduce protein adsorption, 
particularly apolipoprotein J and complement protein C3, through hydrophilicity and steric 
repulsion effects, with the effect of extending circulation time in blood [22–24]. This has 
allowed the “stealth” NP carriers to persist in the bloodstream long enough to reach or 
recognize their therapeutic site of action [25]. Examples of stealth nanocarriers include 
PEGylated liposomal doxorubicin (Doxil®) and the PLA-PEG micelle form of paclitaxel 
(Genexol-PM®). Since the first PEGylated nanomedicine, Doxil®, was approved in 1995, 
many of the current FDA-approved NPs and NPs in clinical trials have begun to carry the 
PEG modification. In addition to PEGylation, new biomaterials and delivery strategies have 
been developed to prolong the circulation time of NPs [26–29]. For example, zwitterionic 
polymer-based NPs are resistant to non-specific protein adsorption, due to electrostatically 
induced hydration [30,31]. Modification of the zwitterionic polymer with a pH-switchable 
moiety allows the NP surface charge to be altered and recognizable by tumor cells, based on 
pH differences between normal tissue and the tumor microenvironment [31]. The switchable 
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surface charge of these particles allows more efficient cellular uptake than the highly 
hydrophilic PEG NP [26,27,31].
One concept prevalent in scientific innovation is the notion of borrowing from nature. The 
longest circulation time achieved by synthetic particles in clinical trials is under 300 hours, 
whereas the human red blood cell circulates for 100–120 days in the body [32]. This is 
mainly because the membrane protein CD47, a “self-marker” on cell membranes (including 
red blood cells of humans, mice, and other mammals), signals the phagocyte receptor 
CD172a, preventing cells from being phagocytosed [33]. NPs modified with a synthetic 
minimal “self” peptide that was computationally designed based on human CD47 showed 
prolonged circulation half-life in a mouse model [33]. Further research extended this 
concept to prolong the residence time of NPs in vivo by coating PLGA NPs with erythrocyte 
membranes that incorporated the mouse’s own membrane lipids and membrane proteins 
(Figure 2). Preliminary preclinical tests showed that these novel NPs had a longer 
circulation half-life than PEG-coated NPs [34]. Although more research is necessary, 
zwitterionic and erythrocyte-coated NPs may become viable PEG substitutes, as zwitterions 
offer increased uptake, and erythrocytes pose little risk of immunogenicity from the patients’ 
own somatic cells.
Nanoformulation and controlled release
Nanoformulation is an important opportunity to revisit promising molecular entities that 
failed in the development process due to poor pharmaceutical properties such as high 
cytotoxicity or poor cellular uptake. A recent example is CRLX101, which is a polymer-
based NP containing Camptothecin (CPT) conjugated to a cyclodextrin-containing polymer 
(CDP) for the treatment of solid tumors [35]. Unfavorable cytotoxic effects led to the 
shelving of development of CPT in spite of clear efficacy in tumor suppression. The 
CRLX101 NP displays a sustained intracellular release profile, which lowers systemic 
exposure and significantly decreases CPT toxicity [35]. The phase I/IIa study shows low 
levels of toxicity and promising anti-tumor activity [35]. CRLX101 partly solves the 
decades-long problem of CPT toxicity by using NPs to release a controlled amount of CPT 
over a longer period of time. Many promising drugs such as camptothecin and wortmannin 
failed clinical development because they did not meet toxicity, stability, or solubility 
requirements. Nanomedicine has the potential to solve these problems and revive abandoned 
cancer drugs for clinical use [36].
Passive targeting
A major benefit of nanomedicine is the improved biodistribution of therapeutic agents 
through passive targeting, a defining feature of first-generation NPs. The enhanced 
permeability and retention (EPR) effect refers to the fact that tumors retain more polymeric 
NPs, proteins, liposomes, and micelles than other tissues [10,37,38]. Most tumors have an 
abnormally dense and permeable vasculature created through stimulation by vascular 
endothelial growth factor (VEGF). Tight junctions in normal vasculature prevent particles 
larger than 2 nm from crossing between endothelial cells. However, the tight junctions and 
basement membrane of tumor vasculature are disordered, allowing entities from 10–500 nm 
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in size to extravasate and accumulate within the tumor interstitium [39,40]. The lymphatic 
drainage system is also impaired in tumors, further entrapping macromolecular particles and 
delaying their clearance [41,42]. Passive targeting is based on both the minute size of drug 
carriers as well as the leaky neovasculature of the tumor (Figure 3). With the longer blood 
circulation brought about by “stealth” modification (e.g. PEGylation), increased 
accumulation of NPs is possible through the EPR effect [39].
Though the notion of utilizing NPs for therapeutic purposes has existed for decades, 
nanotherapeutics that have reached the market have met with varying degrees of success 
[43]. Doxil® was approved for clinical use in 1995 to treat AIDS-related Kaposi’s sarcoma, 
ovarian cancer, and other cancers [44]. Encapsulating doxorubicin within PEGylated NPs 
allows for extended circulation half-life and higher tumor concentration of the drug. Homing 
to the disease site is driven solely by the particles' nano-dimensions through the EPR effect 
[45] rather than any specific recognition of the target. Another example of a passive-
targeting nanomedicine is Genexol-PM®, a polymeric micelle delivery system whose 
formulation includes poly(D,L-lactide), which allows for controlled release of therapeutic 
(Genexol-PM® was approved in Korea in 2007).
ALN-TTR02 is a lipid nanoparticle (LNP) that encapsulates siRNA targeting a conserved 
sequence in the 3’ untranslated region of the transthyretin (TTR) gene. The NP structure 
consists of a neutral lipid, a PEG lipid, and an ionizable cationic lipid to facilitate 
encapsulation of negatively charged siRNA through electrostatic interactions [46]. It is used 
to treat transthyretin amyloidosis, a condition produced by a mutant TTR gene that causes 
the accumulation of transthyretin amyloid in peripheral nerves and the heart [47]. Phase II 
trials showed higher knockdown and continuing suppression of TTR with varying single 
doses as compared to placebo. The therapy seems to be generally safe, with no serious 
adverse events yet reported [47]. However, ALN-TTR02 targets delivery to the liver, which 
is already a proven site of NP accumulation due to reticuloendothelial system uptake. There 
is still progress to be made to treat diseases requiring the differential biodistribution of 
therapeutics.
TKM-PLK1 is another lipid nanoparticle similar in structure to ALN-TTR02, encapsulating 
siRNA that inhibits the protein product polo-like kinase 1 (PLK1). PLK1 phosphorylates 
Cdc25C, regulates DNA damage checkpoints, microtubule nucleation, chromosomal 
condensation and segregation, and is an important target for therapeutic treatment [48]. This 
nanoformulation is significant because it does not rely on accumulation in the organs of the 
reticuloendothelial system (such as the liver) to deliver its payload. TKM-PLK1 relies 
mainly on the EPR effect to localize NPs into solid tumors, with encouraging results [49]. 
Phase I trials measured the effects of dose escalation on solid tumors in advanced cancer 
patients with promising safety and efficacy results, culminating in an ongoing phase II 
clinical trial for patients with advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) 
or Adrenocortical Carcinoma (ACC).
NP therapeutics in clinical trials are clearly an improvement over current treatments. ALN-
TTR02 uses gene silencing to knock out mutant TTR production. This shows promise as a 
viable alternative to invasive procedures for TTR-mediated amyloidosis such as liver 
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transplantation, as well as offering a possible co-treatment with TTR stabilizers such as 
diflunisal. TKM-PLK1 is delivered systemically to solid tumors, and the phase I trials 
targeting PLK-1 for tumour proliferation have had generally positive results. Due to the 
specific sizes of the NPs described above, the EPR effect combined with hemodynamic and 
diffusive mechanisms contributes to the longer blood circulation and accumulation of NPs in 
the tumor. However, passive targeting has a number of drawbacks. Suboptimal 
biodistribution, with particles being trapped mainly in the liver and spleen due to 
reticuloendothelial function, is a major impediment to efficient delivery. In addition, the 
extent of the EPR effect varies from tumor to tumor and even intratumorally, due to the 
heterogeneity and vascular permeability differences within an individual tumor [40,50]. 
Furthermore, the higher interstitial pressure within the tumor core causes the NPs to flow 
from the inner regions to the outer regions, further exacerbating this issue [10]. Two major 
challenges must be resolved in targeted delivery: further extending blood circulation times 
and homing the NPs towards specific sites of targeting for intracellular delivery. Therefore 
efforts are needed to synergize passive targeting with a more dynamic method capable of 
further improving accumulation of NPs at disease sites.
Active targeting nanomedicine
Even with the improvements in biodistribution offered by the EPR effect and PEGylation, 
the majority of a therapeutic (upwards of 90%) will inevitably be concentrated in the 
reticuloendothelial organs such as the liver and spleen due to clearance by mononuclear 
phagocytes [51]. Active targeting is being explored as a method to achieve spatial 
localization by intentionally homing NPs to active diseased sites while eliminating off-target 
adverse effects in normal tissue. The polyvalent decoration of a NP's surface with a ligand 
can facilitate binding to a biomarker specifically overrepresented in targeted cells and 
trigger receptor-mediated endocytosis (Figure 3), a process that has considerable 
implications for targeted delivery [5]. The ligands used to modify NPs include antibodies 
(Figure 4), engineered antibody fragments, proteins, peptides, small molecules, and 
aptamers [52]. The specific ligand-receptor interaction can be utilized to concentrate a 
therapeutic nanomedicine at a diseased tissue in vivo, producing a preferred distribution 
profile [3,53]. The ligand density can be fine-tuned in the formulation process to optimize 
avidity [10,54].
A few active targeting nanoplatforms making use of ligand-receptor interactions have made 
their way to clinical trials. The first targeted NP delivery system to feature siRNA was 
CALAA-01, which consists of a cyclodextrin-containing cationic polymer, a PEG corona, 
and human transferrin (Tf) as a targeting ligand [55]. The Tf on the nanoparticle surface 
binds to overexpressed transferrin receptors (TfR) on cancer cells, and the nanoparticles are 
then internalized via receptor-mediated endocytosis. These siRNA-containing targeted 
nanoparticles were administered intravenously to melanoma patients, upon which they 
circulated in the body and localized in tumors [55,56]. Tumor biopsies showed a correlation 
between the dose administered and the amounts of intracellularly localized NPs. 
Furthermore, levels of both the specific messenger RNA and the protein were lower after 
injection of the targeted nanoparticles. In this study, TfR was used as a potent target; it is 
typically upregulated on cancer cells and triggers cellular uptake via clathrin-coated pits. It 
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is also ubiquitously expressed in all types of tissues to satisfy the iron requirements of 
dividing cells. Other examples of ubiquitous receptors, including folate receptors and the 
receptor tyrosine kinase EGFR, have been explored for active targeting delivery of 
nanotherapeutics to tumor cells [57–59].
Biomarkers distinctively expressed by certain organs offer the possibility to further improve 
the specificity of nanomedicine treatments. Prostate-specific membrane antigen (PSMA) is a 
good example of such a tissue-specific receptor. BIND-014, a targeted nanomedicine 
functionalized with the PSMA-specific ligand, is currently in human clinical trials. It is a 
polymeric nanoparticle encapsulating docetaxel (DTXL) for solid tumor treatment. This 
nanoparticle is modified with a PSMA substrate analog inhibitor, S,S-2-[3-[5-amino-1-
carboxypentyl]-ureido]-pentanedioic acid (ACUPA), specific to PSMA, which is 
upregulated on prostate cancer cells. In Phase I clinical trials, BIND-014 displays promising 
results in patients with advanced or metastatic large tumors [1]. Encouragingly, tumor 
recession has been observed in patients with cancer unresponsive to other treatments [60]. 
The enhanced therapeutic index of DTXL was mainly attributed to PSMA targeting, which 
is consistent with preclinical results. Phase II clinical trials of BIND-014 are under 
investigation for treatment of metastatic drug-resistant prostate cancer and non-small cell 
lung cancer. Other specific targets have been investigated for targeted drug delivery. For 
example, the increasing availability of monoclonal antibodies has fostered interest in 
antibody-functionalized nanomedicines for many years [61,62].
Active targeting with nanoparticles has yielded promising findings in preclinical studies and, 
in some cases, early clinical trials. On the other hand, some studies involving nanoparticle 
targeting have been inconclusive, and therapeutic efficacy in humans has not yet been 
convincingly demonstrated overall [3,51,63]. The protein corona that forms around an NP as 
it interacts with physiological proteins in the body as well as factors that interrupt the 
orientation and proper display of the targeting ligand are two variables that highlight the 
need for further studies of the clinical relevance of actively targeted nanomedicine [3,63].
Nanoparticle-based Combination Therapy
Cancers are very complex diseases involving multiple pathways, and their progression is 
marked by many successive mutations in a line of cells. In addition, since mutations 
favorable to the survival of tumor cells are selected as chemotherapy progresses [64], tumors 
often present such challenges as intrinsic and acquired resistance to chemotherapeutics. 
Therefore the inhibition of a pathway by a single drug may not be sufficient to bring about 
tumor recession. In combination chemotherapy, the synergistic effect of two (or more) 
agents targeting different disease pathways, genes, or cell-cycle checkpoints in the cancer 
process are leveraged to raise the chances of eliminating cancer (Figure 3). The combination 
of chemotherapy medications allows oncologists to use drugs at lower doses, reducing 
cytotoxic effects but increasing efficacy, and therefore present a promising approach for 
cancer research [10]. In practice, combination chemotherapy results in a better response and 
improved survival compared with single-agent therapy; recent examples include the 
combination of Platinol (cisplatin) and Navelbine (vinorelbine) to treat non-small cell lung 
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cancer and TCH (Taxol, Carboplatin and Herceptin) for treatment of HER2/neu-positive 
tumors [65,66].
Nevertheless, the effective administration of multiple drugs at an optimized dosage ratio is 
complicated by dissimilar pharmacokinetics and biodistribution, due to different rates of 
metabolism within the body [67]. Nanoformulations can help avoid such limitations by 
carrying (in one NP) multiple therapeutic agents with different physicochemical properties 
and pharmacological behaviors. In addition, NPs are able to maintain the optimized 
synergistic drug ratio in a single carrier up to the point of intracellular uptake to the target 
cancer cell. This ratio may not be maintained by the use of separate carriers, which each 
encapsulate a different drug. Currently this novel “two-in-one” approach is under clinical 
and preclinical investigation.
CPX-351 is a liposomal NP for the treatment of acute myeloid leukemia designed to 
incorporate the chemotherapy drugs cytarabine and daunorubicin in an optimized 5:1 molar 
ratio. Such a combination has previously been used clinically with small-molecule drugs, 
but the efficacy was limited by unsuitable pharmacokinetics and poor solubility, requiring 
co-administration with toxic solvents [68]. In phase I and II trials, CPX-351 increased 
overall survival in first-relapse patients [69] and is currently in phase III clinical trials. Other 
combinations such as CPX-1 (irinotecan/floxuridine) and paclitaxel/tanespimycin are under 
preclinical/clinical investigation [68,70,71].
Combinatorial therapies involving both siRNA and miRNA have the potential benefit of 
dual inhibition of a target gene product, as well as modulation of oncogenes within the same 
pathway. A team used univariate Cox regression analysis and multiple miRNA target 
prediction programs on a dataset from a previous ovarian cancer study to identify miRNA 
candidates likely to improve antitumor potency when combined with EphA2 targeting 
siRNA [72]. EphA2 is overexpressed in ovarian cancer and is associated with shorter 
median survival [73]. In a mouse model, the chosen miRNA:siRNA combination was 
delivered via a neutral liposomal nanocarrier composed of 1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine (DOPC) and demonstrated tumorsuppressive effect superior to either 
miRNA or siRNA alone [72]. In addition, a multiple siRNA combination therapy recently 
demonstrated increased efficacy in phase I clinical trials [74]. The combination of siRNA 
and miRNA technologies is a significant step toward realizing the full potential of RNAi 
therapies.
The combination of chemotherapy with RNAi is also a promising synergistic strategy for 
cancer treatment. Recently, a polymeric NP platform composed of an aqueous inner core, a 
cationic and hydrophobic PLGA layer, and a hydrophilic PEG corona was developed to 
circumvent acquired chemoresistance by simultaneously delivering a cisplatin prodrug and 
REV1/REV3L-specific siRNAs, which suppress gene targets crucial to translesion synthesis 
(TLS) pathways in tumors [75]. Most mutations that result from DNA damage are the 
consequence of error-prone TLS DNA synthesis, which plays a significant role in cisplatin-
induced mutations. This eventually results in acquired chemoresistance by improving the 
capacity of tumor cells to either repair or tolerate DNA damage [76,77]. NPs were shown to 
synergistically suppress the target genes involved in TLS, resulting in tumor cell 
Xu et al. Page 8
Trends Mol Med. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
sensitization to chemotherapeutic and tumor inhibition in a mouse model that was more 
effective than cisplatin monotherapy. Though this smallmolecule drug/siRNA approach is 
still far from clinical evaluation, it presents a robust platform that not only screens and 
validates target pathways involved in drug resistance, but also achieves an efficacy that may 
not be possible with dual-drug or RNAi combinations alone.
Concluding Remarks and Future Perspectives
In conventional oral or intravenous drug delivery of small-molecule drugs, the medicine is 
distributed indiscriminately throughout the body, with arbitrary concentrations reaching both 
the disease site and healthy tissue. Chemotherapeutic agents in general cause unintended 
adverse effects to healthy tissue and require a trade-off between optimal disease treatment 
and patient quality of life. Nanoparticle-based drug delivery systems offer revolutionary 
opportunities to develop highly effective targeted therapeutics with improved circulation 
half-life, bioavailability, biodistribution, pharmacokinetics, and safety profiles. In addition, 
nanoparticles are indispensable in maintaining synergistic drug ratios in combinational 
therapy and offer the first possibility of delivering therapeutic agents such as nucleic acids 
and unstable proteins. The codelivery of adjuvants with antigens to tumors promotes 
antigen-specific immune responses against the cancer and is yet another facet of the 
numerous nanoparticle anticancer therapies in development [78]. However, there is still 
much to be learned in the emerging field of nanomedicine. We have yet to develop a carrier 
that can effectively deliver a payload intratumorally with clinically validated results. 
Extending circulation closer to the time scale of red blood cells and retention of particles at 
the disease site rather than the reticuloendothelial organs remain significant challenges.
Advances in nanomedicine occur through the development of novel nanocarriers and 
technologies for drug delivery. An ideal nanocarrier should fit the following profile: (i) 
biodegradable and biocompatible; (ii) capable of effective homing, with the majority of 
therapeutics localized within the target site; (iii) designed with optimal biophysicochemical 
properties for superior drug loading, circulation half-life, and sustained drug release across 
infrequent administration times; and (iv) amenable to cost-effective scale-up for 
commercialization. The refinement and incorporation of these qualities in one nanocarrier is 
the “holy grail” of nanomedicine, synthesizing cutting-edge knowledge and technologies 
from the disciplines of medicine, chemistry, engineering, and physics.
Besides the complications in the experimental design of nanoparticles, there exist multiple 
challenges in the manufacturing, regulation, and approval of NPs for clinical use. 
Compliance with quality-control guidelines such as good laboratory quality practice (GLP), 
good manufacturing practice (GMP), as well as passing the three phases of FDA 
Investigational New Drug trials will be challenging in bringing a new nanoformulation to 
market [6]. Moreover, patent disputes are becoming more frequent as more companies 
acquire broad patent rights on a wide range of nanoparticle compositions and usage methods 
[79].
Yet these challenges in nanomedicine are accompanied by new opportunities as well. The 
field of cancer nanomedicine has begun to experience success in clinical applications and 
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has yet to reach its full potential. There is mounting evidence that effective encapsulation of 
small-molecule drugs, nucleic acids, or other compounds may be capable of mediating 
comprehensive cancer management, or even a potential cure [6]. The virtually limitless 
modular possibilities for different ligands, materials, and therapeutic nanoformulations 
coupled with improved treatment efficacies allow us to consider NPs not just drug delivery 
vehicles, but an entirely new class of therapeutics [10]. The broad range of diseases NPs are 
capable of treating, the considerable amount of important research yet to be carried out, and 
the potential to commercialize novel formulations are undoubtedly important "draws" for the 
brightest minds in research. There is still “plenty of room at the bottom”. The era of 
nanomedicine is poised to mature in the next few decades; incorporating elements of 
personalized medicine, it will affect the therapeutic world in a powerful and permanent way.
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Glossary
Active targeting The targeted homing of nanoparticles to sites of disease by way of 
modifying the surface of the particle with ligands specific to 
biomarkers overrepresented in target cells.
Amphiphilic Possessing both hydrophilic and hydrophobic parts.
Combinatorial 
nanodelivery
The delivery of more than a single therapeutic in one particle, often 
in an optimized ratio for synergistic effect. Multiple cancer 
pathways may be targeted with one particle.
Liposome A spherical vesicle composed of a lipid bilayer.
Microfluidics A technology used to quickly fabricate uniform nanoparticles by 
manipulating minute amounts of liquids via channels on the 
micrometer scale.
Mononuclear 
phagocyte system 
(MPS)
The MPS, also called the reticuloendothelial system, consists of the 
phagocytes located in reticular connective tissue present in the 
liver, lymph nodes and spleen which are responsible for the 
eventual clearance of the majority of nanoparticles.
Nanomedicine The design and development of therapeutics and diagnostic tools, 
distinguished by the nanoscopic scale of its delivery vehicles and 
diagnostic agents.
Nanoparticle Particles, usually composed of lipid or polymer, typically less than 
200 nm in diameter.
Passive 
targeting/EPR 
Effect
Refers to the observation that the permeable vasculature and 
disordered basement membrane of tumor tissue leads to preferential 
accumulation of entities 10–500 nm in size.
PLGA Poly(D,L-lactide-co-glycolide) is a commonly used polymer for the 
construction of nanoparticles, usually selected for its controlled 
release capabilities.
Polyethylene 
glycol (PEG)
PEG is a polymer used to modify the nanoparticle surface, resulting 
in the prevention of non-specific binding to blood components. 
These “stealth” particles are better able to evade clearance by cells 
of the MPS.
RNA interference 
(RNAi)
RNAi is a pathway in eukaryotic cells where short pieces of RNA 
are able to induce the breakdown of the complementary mRNAs.
Zwitterionic 
polymer
A polymer which is capable of exhibiting both positive and 
negative charges, and has been shown to resist non-specific protein 
adsorption.
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Highlights
Nanomedicine brings new solutions for cancer therapy
Nanomedicine has the potential to target specific cells for chemotherapeutic treatment
Stealth tech can enhance circulation half-life and controlled release of therapeutic
Drug/RNAi combinatorial strategies show promising synergistic effects.
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Figure 1. Schematic of a system in which nanoparticle (NP) precursors enter a multi-inlet mixer 
at different ratios to self-assemble a library of NPs
Programmable mixing of polymer precursors allows for synthesis of NPs with a wide range 
of sizes, surface chemistry, charge, and targeting agent densities. Adapted with permission 
from [16].
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Figure 2. Red blood cell membrane–coated PLGA NPs
Cellular membranes provide a robust natural functionality to the particle. In comparative 
studies with PEG-coated NPs, RBC membrane–coated NPs exhibited a 39.6-hour half-life 
compared with 15.8 hours for PEG NPs. Adapted with permission from [34].
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Figure 3. Passive targeting, active targeting, and combinatorial delivery
In passive targeting (left), the NPs passively extravasate though the leaky vasculature via the 
EPR effect and preferentially accumulate in tumors. In active targeting (middle), targeting 
ligands on the surface of the NP trigger receptor-mediated endocytosis for enhanced cellular 
uptake. In combinatorial delivery (right), two or more therapeutic agents inhibit different or 
identical disease pathways for a synergistic effect.
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Figure 4. 
Antibody functionalization and visualization. (a) Antibodies conjugated to the NP surface 
through “click” chemistry. (b) Cells that express the complementary antigen are blue and 
show Ab-facilitated binding of targeted NPs. Cells that do not express the complementary 
antigen are green with no NP binding. (c) Fluorescence microscopy images of huA33 
mAbAzfunctionalized nanocapsules with (i) the antibody labeled with AF647 (red), or (ii) 
antibody labeled with AF488 (green), (iii) brightfield, and (iv) overlay images. Adapted with 
permission from [61].
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Table 1
Nanomedicines in clinical development
Targeting
ligand
Therapeutic
encapsulated
Indication Clinical
status
Liposomes
ALN-TTR02 (NCT01559077) Passive siRNA Transthyretin amyloidosis Phase II
CALAA-01 (NCT00689065) Transferrin siRNA Solid tumors Phase I
CPX-351 (NCT00822094) Passive Cytarabine and daunorubicin Acute myeloid leukemia Phase III
MBP-426 (NCT00964080) Transferrin Oxaliplatin Gastroesophageal adenocarcinoma Phase II
SGT53-01 (NCT00470613) Antibody fragment p53 gene Solid tumors Phase I
TKM-PLK1 (NCT01262235) Passive siRNA Solid tumors Phase II
Polymeric NPs
BIND-014 (NCT01300533) Small molecule Docetaxel Solid tumors Phase II
Atu027 (NCT01808638) Protein kinase N3 siRNA Solid tumors Phase II
CRLX-101 (NCT01380769)/(NCT00333502)/(NCT02010567) Passive Camptothecin Non-small cell lung cancer/rectal 
cancer/renal cell carcinoma
Phase II
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